Postmenopausal Vaginal Atrophy PVA Drugs Market show exponential growth by 2023
Request Sample Copy of the Report@
The treatment generally involves use of hormonal replacement therapy, estrogen creams, pessaries or lubricating gels. The sensitivity of urogenital tract to the decline in estrogen levels leads to symptoms related to vaginal atrophy, and is also known to affect sexual function and quality of life in about half of all postmenopausal women. Most commonly, vaginal atrophy becomes evident 4–5 years post the menopause. The principles of treatment in women with established vaginal atrophy are restoration of urogenital physiology, and alleviation of symptoms.
The global PVA drugs market can be segmented based on therapy type, pipeline analysis and geography. Therapy type includes estrogen based and non estrogen based. Commonly used estrogen based therapy includes topical estrogen and systemic estrogen. Various formulations used in topical therapy include creams, tablets and rings, while systemic therapy includes oral administration of estradiol. Vaginal creams and vaginal tablets are the most commonly used therapies. However, topical estrogen treatment is known to cause endometrial cancer in few women Oral estradiol use since associated with adverse events such as deep vein thrombosis, stroke, Coronary Heart Disease (CHD), and invasive breast cancer is least preferred treatment option. Recent novel drugs in non estrogen category include Osphena (osphemifene), BZA/CE (bazedoxifene + conjugated estrogens) and Vaginorm (prasterone). Estrogen replacement therapy producst include Premarin, Vagifem, Estrace, Estring and Femring. Geographically, the global PVA drugs market can be segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World.
Historically, PVA has witnessed several unmet needs due to low diagnosis rate, poor patient compliance and the risk associated with the existing treatment to cause different cancers. Also, the reluctant nature of women to discuss with healthcare professionals regarding symptoms such as vaginal burning vaginal dryness, and discomfort during intercourse was known to result in low diagnosis and treatment-seeking rate. However with the advent of novel drugs with improved safety are expected to tap the unmet needs by increasing the number of women undergoing treatment. Increase in awareness of postmenopausal vaginal Atrophy amongst patient as well as physicians regarding the need for treatment, shift towards use of non-estrogen based therapies and conducting awareness campaigns is likely to boost the PVA drugs market during the forecast period. Novel drug are further expected to improve patient compliance through enhanced safety and efficacy profiles and therefore drive the global postmenopausal Atrophy drugs market.
Some of the key players contributing to the global postmenopausal vaginal Atrophy drugs market include Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer, Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., and Shionogi & Co. Ltd.
Request TOC of the Report@
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market projections for upcoming years
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
You can edit or delete your press release Postmenopausal Vaginal Atrophy PVA Drugs Market show exponential growth by 2023 here
News-ID: 763622 • Views: 90
More Releases from Transparency Market Research
Impact of Outbreak of COVID-19 on Medical Education Market : Global Industry Ana …
Transparency Market Research (TMR) has published a new report on the medical education market for the period of 2019–2027. According to the report, the global medical education market was valued at nearly US$ 31 Bn in 2018, and is projected to expand at a CAGR of more than 4% from 2019 to 2027. Rise in the number of medical schools and increase in cost of medical education are the
Healthcare BI Platform Market Companies Analysis, Advancement and Precise Outloo …
In an intensely competitive healthcare business intelligence (BI) platform market, large players are aggressively focused on expanding their geographical outreach, says Transparency Market Research (TMR) in a new market intelligence report. These large players are leveraging the cloud business model to provide healthcare BI solutions that can be accessed irrespective of location. Apart from this, savvy players are entering into partnerships with hospital groups and healthcare bodies to integrate healthcare BI
Substance Abuse Treatment Market News Research Report 2024
A recent report by Transparency Market Research on the substance abuse treatment market in the U.S. states that the competitive landscape is highly fragmented. This is because around 242 companies compete against one another in it. This also makes overall competition stiff. Some of the companies that have beat competition to emerge as leading players in the market are Pfizer Inc., Alkermes Plc, GlaxoSmithKline Plc., and Purdue Pharma LP. Their
Clinical Oncology Next Generation Sequencing Market is Thriving Worldwide By Siz …
Clinical Oncology Next Generation Sequencing: Introduction Next generation sequencing for tumor and germline DNA is required for oncology screening for therapeutic application. Rise in burden of cancer increases the need for early detection of the condition to carry out the generate target therapy. Companies are investing to develop technologically advanced devices/solutions for precision detection. In 2012, Oxford Nanopore had launched the GridION sequencing platform, which can sequence a human genome in 15
More Releases for Atrophy
Spinal Muscular Atrophy Market | SMA Treatment Market | PBIGP
Spinal Muscular Atrophy Management Market is Expected to Increase Around US$ XX Mn by 2025, Due to Inherited Diseases that Affects the Functioning of Muscles Because of Deterioration. Analyst Speak: “The Spinal Muscular Atrophy Management Market is anticipated to reach about US$ XX Mn by 2024, and anticipated to expand at a CAGR over seven years of forecast period 2019-2025” due to increased inherited diseases that affects the normal functioning of
Spinal Muscular Atrophy Market: Pipeline Drugs to Enhance Market Growth
The global spinal muscular atrophy market consists of a decent number of market players who are engaged in developing novel medications for the treatment of the disorder. The efforts of the leading market players are reflected in the success rate of treatments in the past and the level of trust garnered by the vendors from the customers. The medical industry works in proximity with the market for spinal muscular atrophy
Geographic Atrophy - Pipeline Review, H2 2018 - ResearchByMarkets.com
"Geographic Atrophy - Pipeline Review, H2 2018", provides an overview of the Geographic Atrophy (Ophthalmology) pipeline landscape. Geographic atrophy is an advanced form of age-related macular degeneration that can result in the progressive and irreversible loss of retina which can lead to a loss of visual function over time. Symptoms include difficulty during reading. Risk factors include smoking, thyroid hormones or antacids and in patients with coronary heart diseases and cataract
Global Multiple System Atrophy Therapeutics Market Manufacturers Analysis 2025
Qyresearchreports include new market research report "Global Multiple System Atrophy Therapeutics Market Professional Survey Report 2018" to its huge collection of research reports. A report on the global market for Multiple System Atrophy Therapeutics is a valuable repository of various crucial facts and figures pertaining to the market. The information was collated after thorough primary and secondary research by a clutch of expert analysts. Not only did they gather useful information
Key Growth Strategies Adopted in Spinal Muscular Atrophy Market
A new report, titled “Spinal Muscular Atrophy Market - Pipeline Assessment, Size, Growth, Trends, and Forecast 2015 - 2023” has been published by Transparency Market Research. The study offers a detailed analysis of the spinal muscular atrophy market, providing insights into the pipeline assessment, major growth drivers, restraints, and potential opportunities. According to the research study, the spinal muscular atrophy phase three candidate ISIS-SMNRx is projected to generate revenue of
Spinal Muscular Atrophy Market : Expected Advancements & Global Industry Analysi …
Pipeline analysis of spinal muscular atrophy (SMA) market report provides with comprehensive analysis of drugs in clinical trials for treatment for spinal muscular atrophy. The report provides insights to SMA prevalence, and current treatment pattern. The report also identifies key market drivers, restraints and opportunities in the global spinal muscular atrophy therapeutics market. Detailed market attractiveness analysis by geography provides future outlook to the spinal muscular atrophy landscape. Market attractiveness